Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
CONCORDBIONSE
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 11% | 7% | -12% |
| - | 2% | 3% | -30% |
| - | - | -5% | -23% |
| 20% | 19% | 19% | 14% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
CONCORDBIO
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 554.1 | ₹11638 Cr | 41.2 | 3.38 | 17.07 | ₹261 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹309 Cr | ₹257 Cr | ₹326 Cr | ₹278 Cr | ₹247 Cr | ₹204 Cr | ₹430 Cr | ₹244 Cr | ₹310 Cr | ₹216 Cr | ₹319 Cr | ₹241 Cr | ₹262 Cr | ₹195 Cr | ₹273 Cr | ₹241 Cr | ₹159 Cr | ₹181 Cr |
| ₹10 Cr | ₹13 Cr | ₹15 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹9 Cr | ₹15 Cr | ₹10 Cr | ₹10 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹12 Cr | ₹9 Cr | ₹6 Cr | ₹8 Cr |
| ₹319 Cr | ₹270 Cr | ₹341 Cr | ₹288 Cr | ₹260 Cr | ₹218 Cr | ₹439 Cr | ₹259 Cr | ₹320 Cr | ₹226 Cr | ₹330 Cr | ₹249 Cr | ₹270 Cr | ₹201 Cr | ₹285 Cr | ₹250 Cr | ₹165 Cr | ₹189 Cr |
| ₹223 Cr | ₹193 Cr | ₹227 Cr | ₹198 Cr | ₹177 Cr | ₹160 Cr | ₹254 Cr | ₹160 Cr | ₹187 Cr | ₹148 Cr | ₹198 Cr | ₹148 Cr | ₹156 Cr | ₹136 Cr | ₹158 Cr | ₹143 Cr | ₹133 Cr | ₹130 Cr |
| ₹115 Cr | ₹95 Cr | ₹134 Cr | ₹109 Cr | ₹102 Cr | ₹75 Cr | ₹200 Cr | ₹113 Cr | ₹147 Cr | ₹92 Cr | ₹145 Cr | ₹114 Cr | ₹127 Cr | ₹79 Cr | ₹141 Cr | ₹121 Cr | ₹44 Cr | ₹72 Cr |
| ₹3 L | ₹4 L | ₹8 L | ₹8 L | ₹6 L | ₹6 L | ₹10 L | ₹10 L | ₹10 L | ₹24 L | ₹46 L | ₹50 L | ₹84 L | ₹75 L | ₹1 Cr | ₹91 L | ₹1 Cr | ₹1 Cr |
| ₹96 Cr | ₹77 Cr | ₹114 Cr | ₹87 Cr | ₹83 Cr | ₹57 Cr | ₹185 Cr | ₹99 Cr | ₹133 Cr | ₹78 Cr | ₹131 Cr | ₹100 Cr | ₹113 Cr | ₹65 Cr | ₹126 Cr | ₹106 Cr | ₹30 Cr | ₹58 Cr |
| ₹70 Cr | ₹56 Cr | ₹89 Cr | ₹64 Cr | ₹61 Cr | ₹43 Cr | ₹142 Cr | ₹74 Cr | ₹99 Cr | ₹58 Cr | ₹97 Cr | ₹75 Cr | ₹84 Cr | ₹48 Cr | ₹94 Cr | ₹79 Cr | ₹22 Cr | ₹43 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — |
| ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr |
| ₹2007 Cr | ₹1802 Cr | ₹1516 Cr | ₹1280 Cr | ₹1094 Cr | ₹990 Cr | ₹761 Cr |
| ₹2007 Cr | ₹1802 Cr | ₹1516 Cr | ₹1280 Cr | ₹1094 Cr | ₹990 Cr | ₹761 Cr |
| ₹2017 Cr | ₹1813 Cr | ₹1527 Cr | ₹1290 Cr | ₹1103 Cr | ₹999 Cr | ₹770 Cr |
| -₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹31 Cr | ₹56 Cr | ₹36 Cr |
| ₹42 Cr | ₹34 Cr | ₹28 Cr | ₹23 Cr | ₹21 Cr | ₹17 Cr | ₹15 Cr |
| ₹1 Cr | ₹63 L | ₹2 Cr | ₹16 L | ₹31 L | ₹2 Cr | ₹3 Cr |
| ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹48 Cr | ₹37 Cr | ₹32 Cr | ₹32 Cr | ₹54 Cr | ₹77 Cr | ₹55 Cr |
| — | — | — | — | — | — | — |
| ₹102 Cr | ₹113 Cr | ₹94 Cr | ₹94 Cr | ₹83 Cr | ₹46 Cr | ₹71 Cr |
| ₹56 Cr | ₹55 Cr | ₹38 Cr | ₹62 Cr | ₹66 Cr | ₹54 Cr | ₹42 Cr |
| ₹0 | ₹38 L | ₹0 | ₹0 | ₹4 Cr | ₹5 Cr | ₹0 |
| ₹11 Cr | ₹16 Cr | ₹9 Cr | ₹36 Cr | ₹191 Cr | ₹131 Cr | ₹110 Cr |
| ₹169 Cr | ₹184 Cr | ₹142 Cr | ₹192 Cr | ₹344 Cr | ₹236 Cr | ₹223 Cr |
| ₹2232 Cr | ₹2034 Cr | ₹1701 Cr | ₹1514 Cr | ₹1502 Cr | ₹1313 Cr | ₹1049 Cr |
| ₹4 Cr | ₹4 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹4 Cr | ₹4 Cr |
| ₹0 | ₹38 L | ₹6 Cr | ₹31 Cr | ₹61 Cr | ₹86 Cr | ₹48 Cr |
| — | — | — | — | — | — | — |
| ₹1163 Cr | ₹1097 Cr | ₹828 Cr | ₹793 Cr | ₹720 Cr | ₹645 Cr | ₹311 Cr |
| ₹374 Cr | ₹302 Cr | ₹253 Cr | ₹200 Cr | ₹147 Cr | ₹99 Cr | ₹72 Cr |
| ₹789 Cr | ₹795 Cr | ₹575 Cr | ₹593 Cr | ₹573 Cr | ₹546 Cr | ₹240 Cr |
| ₹78 Cr | ₹50 Cr | ₹211 Cr | ₹173 Cr | ₹74 Cr | ₹18 Cr | ₹141 Cr |
| ₹89 Cr | ₹19 Cr | ₹2 Cr | ₹12 L | ₹26 L | ₹37 L | ₹81 L |
| ₹89 Cr | ₹19 Cr | ₹2 Cr | ₹12 L | ₹26 L | ₹37 L | ₹81 L |
| ₹18 Cr | ₹12 Cr | ₹13 Cr | ₹12 Cr | ₹221 Cr | ₹141 Cr | ₹128 Cr |
| ₹7 Cr | ₹23 Cr | ₹3 Cr | ₹9 Cr | ₹82 L | ₹45 L | ₹67 L |
| ₹982 Cr | ₹899 Cr | ₹804 Cr | ₹786 Cr | ₹869 Cr | ₹706 Cr | ₹510 Cr |
| — | — | — | — | — | — | — |
| ₹402 Cr | ₹317 Cr | ₹244 Cr | ₹137 Cr | ₹73 Cr | ₹141 Cr | ₹198 Cr |
| ₹326 Cr | ₹240 Cr | ₹208 Cr | ₹212 Cr | ₹195 Cr | ₹154 Cr | ₹111 Cr |
| ₹460 Cr | ₹522 Cr | ₹350 Cr | ₹274 Cr | ₹232 Cr | ₹178 Cr | ₹184 Cr |
| ₹14 Cr | ₹1 Cr | ₹47 Cr | ₹43 Cr | ₹89 Cr | ₹61 Cr | ₹3 Cr |
| ₹18 Cr | ₹29 Cr | ₹27 Cr | ₹46 Cr | ₹33 Cr | ₹40 Cr | ₹14 Cr |
| ₹30 Cr | ₹27 Cr | ₹21 Cr | ₹16 Cr | ₹10 Cr | ₹34 Cr | ₹29 Cr |
| ₹1250 Cr | ₹1135 Cr | ₹896 Cr | ₹728 Cr | ₹633 Cr | ₹607 Cr | ₹539 Cr |
| ₹1081 Cr | ₹951 Cr | ₹754 Cr | ₹536 Cr | ₹288 Cr | ₹371 Cr | ₹315 Cr |
| ₹2232 Cr | ₹2034 Cr | ₹1701 Cr | ₹1514 Cr | ₹1502 Cr | ₹1313 Cr | ₹1049 Cr |
| ₹193 | ₹173 | ₹146 | ₹123 | ₹1,160 | ₹1,051 | ₹810 |
| ₹193 | ₹173 | ₹146 | ₹123 | ₹105 | ₹96 | ₹74 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| ₹345 Cr | ₹495 Cr | ₹413 Cr | ₹322 Cr | ₹238 Cr | ₹313 Cr | ₹213 Cr |
| ₹37 Cr | ₹30 Cr | ₹37 Cr | ₹47 Cr | ₹53 Cr | ₹18 Cr | ₹12 Cr |
| -₹14 Cr | -₹171 Cr | -₹81 Cr | -₹52 Cr | -₹22 Cr | -₹89 Cr | -₹22 Cr |
| ₹367 Cr | ₹354 Cr | ₹369 Cr | ₹316 Cr | ₹268 Cr | ₹242 Cr | ₹204 Cr |
| ₹267 Cr | ₹245 Cr | ₹265 Cr | ₹246 Cr | ₹207 Cr | ₹167 Cr | ₹155 Cr |
| -₹143 Cr | -₹160 Cr | -₹155 Cr | -₹158 Cr | -₹112 Cr | -₹195 Cr | -₹113 Cr |
| -₹113 Cr | -₹99 Cr | -₹99 Cr | -₹85 Cr | -₹100 Cr | ₹31 Cr | -₹43 Cr |
| ₹11 Cr | -₹14 Cr | ₹12 Cr | ₹3 Cr | -₹4 Cr | ₹3 Cr | -₹1 Cr |
| ₹90 L | ₹15 Cr | ₹3 Cr | ₹67 L | ₹5 Cr | ₹2 Cr | ₹4 Cr |
| ₹12 Cr | ₹90 L | ₹15 Cr | ₹3 Cr | ₹67 L | ₹5 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 oscillators
RSI
34.12Sell
STOCH %K
1.67Buy
MACD Level(12,26)
-29.91Sell
Ultimate Oscillator
36.73Sell
Aroon Oscillator
-80.00Sell
BOP
-0.24Sell
CCI
-134.90Buy
Williams %R
-98.33Buy
Momentum
-33.55Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 9 out of 9 moving averages
EMA 9
575.46Sell
SMA 9
576.80Sell
EMA 21
604.46Sell
SMA 21
609.05Sell
EMA 50
642.71Sell
SMA 50
664.43Sell
EMA 200
669.95Sell
SMA 200
630.83Sell
WMA 20
591.80Sell
Pivot
Pivot
Classic
Resistance 5
603.10
Resistance 4
591.20
Resistance 3
579.30
Resistance 2
567.40
Resistance 1
561.90
Pivot
555.50
Support 1
550.00
Support 2
543.60
Support 3
531.70
Support 4
519.80
Support 5
507.90
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 44.09% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| 7.28% | 7.53% | 7.79% | 7.58% | 8.03% | 9.10% |
| 5.11% | 4.97% | 4.92% | 5.13% | 5.01% | 4.16% |
| 5.84% | 4.40% | 4.30% | 4.44% | 4.53% | 4.68% |
| 37.68% | 39.02% | 38.91% | 38.77% | 38.35% | 37.98% |
Bulk & block deals
Name
Dsp Mutual Fund
1575773 Ontario Inc
Nk Securities Research Private Limited
Nk Securities Research Private Limited
The Vanguard Group Inc A/C Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard Internat
The Vanguard Group Inc A/C Vanguard Total International Stock Index Fund
Ubs Principal Capital Asia Limited
Norges Bank On Account Of The Government Pension Fund Global
1575773 Ontario Inc
Societe Generale
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 31 Aug 2026 | Purchase | 180.86 Cr | ₹1,404.10 | 12.88 L | Bulk | 1.231276 | BSE |
| 31 Aug 2026 | Sell | 293.78 Cr | ₹1,404.10 | 20.92 L | Bulk | 2.000001 | BSE |
| 25 Feb 2026 | Purchase | 75.14 Cr | ₹1,217.94 | 6.17 L | Bulk | 0.589729 | NSE |
| 25 Feb 2026 | Sell | 75.18 Cr | ₹1,218.58 | 6.17 L | Bulk | 0.589729 | NSE |
| 20 Sep 2024 | Purchase | 149.84 Cr | ₹2,596.08 | 5.77 L | Bulk | 0.551715 | NSE |
| 20 Sep 2024 | Purchase | 181.19 Cr | ₹2,596.08 | 6.98 L | Bulk | 0.66714 | NSE |
| 20 Sep 2024 | Sell | 191.69 Cr | ₹2,589.86 | 7.40 L | Bulk | 0.707499 | NSE |
| 28 May 2024 | Purchase | 83.22 Cr | ₹1,386.95 | 6 L | Bulk | 0.573525 | NSE |
| 28 May 2024 | Sell | 483 Cr | ₹1,361.26 | 35.48 L | Bulk | 3.391646 | NSE |
| 25 Jan 2024 | Purchase | 21.81 Cr | ₹1,421.70 | 1.53 L | Block | 0.146651 | BSE |
Insider trading & SAST
Client name
Chandrashekhar Mukundrao Chawan
Prakash Lalchand Sajnani
Devang Bhatt
Kanishka Kapoor
Ravi Kapoor
1575773 Ontario Inc
Rajendra Modi
Raksha Modi
Mr. Chandrashekhar Mukundrao Chawan
Raksha Modi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 Sep 2024 | Designated Person | Disposal | 0.000956 | 0.01 | 21.09 L | ₹2,109.40 | 1 K | 16 Sep 2024 - 22 Sep 2024 | Market Sale | 9,039 | Insider Trading | — | Equity Shares |
| 23 Sep 2024 | Designated Person | Disposal | 0.004779 | 0.02 | 1.08 Cr | ₹2,168.80 | 5 K | 16 Sep 2024 - 22 Sep 2024 | Market Sale | 17,000 | Insider Trading | — | Equity Shares |
| 04 Sep 2024 | Designated Person | Disposal | 0.002868 | 0.01 | 52.04 L | ₹1,734.79 | 3 K | 02 Sep 2024 | Market Sale | 8,056 | Insider Trading | — | Equity Shares |
| 13 Jun 2024 | Directors Immediate Relative | Disposal | 0.009559 | 0 | 0 | — | 10 K | 12 Jun 2024 | Market Sale | 0 | Insider Trading | — | Equity Shares |
| 05 Jun 2024 | Director | Disposal | 0.009559 | 0.2 | 0 | — | 10 K | 04 Jun 2024 | Gift | 2,10,000 | Insider Trading | — | Equity Shares |
| 03 Jun 2024 | Other | Disposal | 3.39 | 2 | 0 | — | 35.48 L | 28 May 2024 | Market | 20,92,325 | SAST | 29(2) | — |
| 27 Feb 2024 | Designated Person | Disposal | 0.003823 | 0.02 | 59.98 L | ₹1,499.52 | 4 K | 26 Feb 2024 | Market Sale | 18,000 | Insider Trading | — | Equity Shares |
| 27 Feb 2024 | Employees Immediate Relative | Disposal | 0.001912 | 0.02 | 29.85 L | ₹1,492.37 | 2 K | 26 Feb 2024 | Market Sale | 18,000 | Insider Trading | — | Equity Shares |
| 24 Feb 2024 | Designated Person | Disposal | 0.000956 | 0.01 | 14.45 L | ₹1,444.90 | 1 K | 23 Feb 2024 | Market Sale | 10,039 | Insider Trading | — | Equity Shares |
| 24 Feb 2024 | Employees Immediate Relative | Disposal | 0.001912 | 0.02 | 29.33 L | ₹1,466.52 | 2 K | 23 Feb 2024 | Market Sale | 20,000 | Insider Trading | — | Equity Shares |
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including
Corporate Actions
Date
Type
Details
Company details
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Concord Biotech Share Price
548.20+0.00 (-1.47%)
-23.21% past 1 Year
News
1 of 20
ResultCONCORDBIO27 Oct 2026
Concord Biotech reported Q2 EBITDA of Rs 110.00 crores, rising 21.49% year on year from Rs 90.54 crores. EBITDA margin declined to 35.16% from 36.65% in the corresponding quarter, indicating operating margin pressure despite strong EBITDA growth. Revenue and PAT figures, along with quarter-on-quarter comparisons and street expectations, were not provided. The result reflects higher absolute operating earnings but weaker EBITDA margin performance during the quarter.
Concord Biotech Reports Stronger Second Quarter Net Profit Growth
ResultCONCORDBIO27 Oct 2026
Concord Biotech reported standalone second-quarter net profit of Rs 75.70 crores, up from Rs 62.90 crores in the corresponding quarter of the previous year, representing year-on-year growth of approximately 20.35%. Revenue, EBITDA, operating margin, net margin, and sequential quarter figures were not provided in the available update and are therefore not included. The earnings outcome indicates improved profitability during the quarter, although no management commentary, consensus comparison, or market reaction was specified.
Concord Biotech Reports Strong Second Quarter Revenue Growth
ResultCONCORDBIO27 Oct 2026
Concord Biotech reported Q2 revenue of Rs 312.00 crores, compared with Rs 247.00 crores in the corresponding quarter of the previous year, representing year-on-year growth of approximately 26.3%. The available update does not provide EBITDA, PAT, operating margin, net margin, quarter-on-quarter comparison, or street expectations.
The revenue increase indicates stronger quarterly operating performance, although profitability trends and management commentary are unavailable in the reported information. Concord Biotech operates in the pharmaceutical and bulk drugs sector, and its NSE symbol is CONCORDBIO.
Concord Biotech Approves One To One Bonus Issue And Raises Capital
Stock NewsCONCORDBIO23 Sept 2026
Concord Biotech has approved a 1:1 bonus share issue, under which eligible shareholders will receive one additional equity share for every one share held. The company has also approved an increase in its authorised share capital to Rs 22 crores. The bonus issue will expand the number of outstanding shares without changing the company’s underlying equity value, subject to applicable approvals and record date determination. The higher authorised capital will provide the required headroom for issuing the bonus shares. The action may improve stock liquidity and broaden retail participation, while having no immediate direct impact on earnings, leverage, or operating capacity. The record date and other implementation details were not provided in the available information.
Concord Biotech Q1 EBITDA rises sharply with improved margin performance
ResultCONCORDBIO31 Jul 2026
Concord Biotech has reported a strong operating performance for the latest reported quarter, with Q1 EBITDA coming in at Rs 87.20 crores compared to Rs 61.40 crores in the corresponding period last year. This reflects a robust year-on-year improvement in operating profitability in absolute terms, indicating better scale, operational efficiency, or a more favourable product mix. While detailed revenue and profit after tax (PAT) numbers are not available in the provided context, the significant rise in EBITDA suggests a healthy underlying business momentum during the quarter.
The company’s Q1 EBITDA margin has also expanded meaningfully, improving to 33.46% from 30.1% on a year-on-year basis. This margin expansion of over 300 basis points points to improved cost control, operating leverage benefits, or better pricing power in its key products and markets. Higher margins at the EBITDA level generally indicate that the core operations are becoming more efficient and that the company is able to convert a larger share of its operating revenue into operating profit before interest, tax, depreciation, and amortisation.
In the absence of disclosed revenue, PAT, or quarter-on-quarter comparisons, as well as any commentary from management or street consensus estimates, the analysis is focused on the reported operating metrics. No information is available in the given context on market reaction, stock price movement on NSE or BSE, or broader sector cues. Nonetheless, the combination of a substantial year-on-year increase in EBITDA and a notable improvement in EBITDA margin indicates a favourable operating trend for Concord Biotech in the reported quarter, based purely on the verifiable figures provided.
Concord Biotech posts strong Q1 revenue growth on robust year-on-year performance
ResultCONCORDBIO31 Jul 2026
Concord Biotech reported a healthy improvement in its quarterly financial performance, with Q1 revenue coming in at approximately Rs 260 crores. This represents a meaningful year-on-year increase compared to revenue of about Rs 204 crores in the same quarter last year, indicating solid demand traction and operational scaling for the company. The sharp rise in topline suggests improved volume growth, better realisation, or a combination of both, reflecting positively on the underlying business fundamentals. However, detailed profitability metrics such as EBITDA, PAT, and margin movements have not been provided in the available context, so a deeper evaluation of operating leverage, cost trends, and net earnings impact cannot be inferred here.
In the absence of explicit data on operating or net margins, it is not possible to comment on whether higher revenue has translated into proportionately stronger profitability or whether increased input costs, R&D expenses, or other operating overheads have partially offset the topline gains. Similarly, there is no information on consensus street expectations or broker estimates for the quarter, meaning any assessment of outperformance or underperformance versus market expectations would be speculative and therefore must be avoided. The available update is focused purely on revenue, without commentary from management on guidance, pipeline, cost structure, or strategic initiatives, and there is no verifiable information provided on the immediate stock price reaction or trading volumes following the result.
Given these constraints, the key takeaway from the disclosed numbers is the strong year-on-year revenue growth in Q1, which is generally supportive for sentiment around Concord Biotech’s business trajectory. The lack of additional detail on margins, earnings, or market reaction means the assessment must remain limited to acknowledging the revenue outperformance versus the prior year’s quarter, without extending into unverified conclusions on overall financial health, valuation, or forward-looking outlook.
Concord Biotech reports higher Q1 net profit on steady quarterly earnings
ResultCONCORDBIO31 Jul 2026
Concord Biotech reported standalone Q1 net profit of Rs 61.20 crores versus Rs 42.50 crores in the same period last year, reflecting a YoY increase in bottom-line earnings. The provided update does not include revenue, EBITDA, or margin figures, so those metrics are not available for comparison.
The result points to improved profitability in the quarter for Concord Biotech, a company listed on NSE/BSE under the equity category. No street estimate, management commentary, or market reaction was provided in the context, so these details are not included.
Concord Biotech schedules Q1 FY2026 earnings conference call for investors
Stock NewsCONCORDBIO28 Jul 2026
Concord Biotech has announced that it will hold its Q1 earnings conference call on August 3 at 3:30 PM. The call is expected to focus on the company’s financial and operational performance for the first quarter of the current financial year, including revenue trends, margin profile, operational efficiencies, and key business developments across its product portfolio. Management is likely to provide commentary on demand conditions in core markets, updates on ongoing projects, and the outlook for the remainder of the financial year.
For investors and analysts tracking Concord Biotech, the scheduled earnings call is an important event to gain deeper insight into the company’s growth trajectory, capital allocation priorities, and potential pipeline or capacity expansion initiatives, if any are discussed. The timing of the call within market hours may facilitate immediate reaction from institutional and retail participants once key performance metrics and management guidance are known. However, ahead of the call, there is no publicly available detail in this context about the quantum of revenue, profit, margins, or any specific corporate actions such as capex plans, M&A, stake sale, buyback, or regulatory orders.
In the absence of disclosed performance numbers or guidance in this news item, the primary significance for the market lies in the opportunity for enhanced transparency and updated communication from the company’s management. The call may help the street refine earnings estimates, reassess assumptions on growth and profitability, and evaluate any commentary on industry dynamics impacting Concord Biotech. Until the actual Q1 results and management commentary are released, the development remains a routine, scheduled corporate event with limited immediate implications for valuation, leverage expectations, or market share assumptions purely on the basis of this announcement.
Concord Biotech clears Kenya, Uganda inspections at Unit-II formulation plant
Stock NewsCONCORDBIO25 Jun 2026
Concord Biotech Limited has announced the successful completion of regulatory inspections at its Unit-II formulation facility by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda. The joint inspection was conducted over the period from June 18, 2026 to June 24, 2026 and concluded without any reported adverse remarks, as disclosed in the company’s regulatory communication. This development confirms that the Unit-II formulation plant complies with the current regulatory and quality standards required by both Kenyan and Ugandan authorities, reinforcing Concord Biotech’s manufacturing and quality systems for export markets.
The successful inspection outcome is strategically positive for Concord Biotech’s formulations business, particularly in African markets where regulatory clearances from PPB and NDA are necessary for product registrations, long-term supplies and potential tenders. With the facility now validated by these regulators, the company is better positioned to pursue or expand commercial opportunities in Kenya, Uganda and other regional markets that reference these agencies. Over time, this may support higher capacity utilization at Unit-II, improved operating leverage and incremental revenues from international formulations, although exact quantum of impact on earnings, margins or cash flows has not been quantified in the available disclosures.
On the market side, the news has coincided with modest stock movement. Recent trading data show Concord Biotech’s shares moving in a narrow band on the BSE, with intraday price fluctuations but no indication of a large index-level impact from this announcement alone. Overall, the development is a routine but clearly positive regulatory milestone for the company, strengthening its compliance credibility and export readiness without altering domestic macro conditions or sector-wide dynamics.
Brazilian Health Regulatory Agency completes inspection at Concord Biotech’s API manufacturing facility in Limbasi
Stock NewsCONCORDBIO12 Jun 2026
The inspection took place from June 8, 2026 to June 12, 2026
Concord Biotech completes Anvisa inspection at Limbasi API site
Stock NewsCONCORDBIO12 Jun 2026
Concord Biotech said it has completed an Anvisa inspection at its Limbasi API manufacturing site, a regulatory step that can improve access to Brazil's pharmaceutical market and support future export growth.
The inspection outcome is relevant because Anvisa approval or clearance is often important for supplying regulated markets in Brazil. For Concord Biotech, the development may strengthen the company’s global footprint and broaden the commercial opportunity for its API manufacturing business, although the exact financial impact has not been disclosed in the available text.
No deal value, capacity addition, or revenue contribution was mentioned in the report. The announcement is a company-specific compliance and market-access update rather than a broader sector or macro event.
Concord Biotech zooms after getting USFDA’s nod for Tofacitinib Tablets
Stock NewsCONCORDBIO10 Jun 2026
Tofacitinib tablets are indicated for the treatment of adult patients with Moderately
Concord Biotech gets USFDA’s nod for Tofacitinib Tablets
Stock NewsCONCORDBIO10 Jun 2026
Tofacitinib tablets are indicated for the treatment of adult patients with Moderately
Concord Biotech gains USFDA nod for Tofacitinib tablets with US sales potential
Stock NewsCONCORDBIO10 Jun 2026
Concord Biotech has received approval from the USFDA for its Tofacitinib tablets, opening up a new regulated market opportunity in the US. Tofacitinib is a key small-molecule therapy used in the treatment of autoimmune conditions, and entry into this product segment strengthens the company’s generic formulations portfolio for advanced markets. The company has indicated a potential US sales opportunity of about Rs 50 crores from this product, reflecting a meaningful incremental revenue stream relative to typical single-product launches in the US generics space. While pricing dynamics in the US generics market can be competitive, the approval itself is an important milestone that can help Concord Biotech scale its international business mix and improve capacity utilization over time.
From a strategic perspective, the USFDA approval demonstrates Concord Biotech’s capability to clear stringent regulatory standards for complex formulations, which can support its credibility for future filings and partnerships. The incremental US revenue potential from Tofacitinib tablets, if realized, could contribute positively to earnings and operating leverage, although the eventual impact will depend on factors such as final pricing, market share, competitive intensity, and launch timelines. No details are available in the given context on launch date, exact dosage strengths, margin profile, or any concurrent corporate actions such as M&A, capex, or buyback linked to this approval. The news specifically highlights product-level regulatory progress and addressable market value, but does not mention any immediate stock price reaction or changes in leverage. Overall, the development adds a new revenue avenue in the US market and reinforces Concord Biotech’s positioning in the specialty generics and APIs space, but the scale of financial impact will only be clear after commercialization and ramp-up.
Concord Biotech soars on getting USFDA nod for Mycophenolate Mofetil for Oral Suspension
Stock NewsCONCORDBIO3 Jun 2026
The U.S. market for Mycophenolate Mofetil is around $3.00 Crores
Concord Biotech gets USFDA nod for Mycophenolate Mofetil oral suspension
Stock NewsCONCORDBIO2 Jun 2026
Concord Biotech has received approval from the USFDA for its Mycophenolate Mofetil oral suspension, a generic formulation used primarily as an immunosuppressant in transplant and certain autoimmune indications. The approval enables the company to commercialise this product in the US market, adding another regulated-market offering to its portfolio. Management is targeting an addressable opportunity of about Rs 3.00 crores from this product in the US, indicating a modest but incremental revenue stream relative to its existing base. While the immediate revenue contribution may be limited, the approval underscores Concord Biotech's execution capabilities in complex formulations and strengthens its presence in the US generics space.
From a strategic standpoint, a new USFDA-approved product can help diversify Concord Biotech's revenue mix and marginally improve operating leverage as US sales scale up over time. The additional product in a specialized therapeutic area may also support the company’s competitive positioning in niche immunosuppressant markets, though pricing pressure and generic competition in the US remain key variables. There is no specific disclosure in the context regarding launch timelines, pricing, margin profile or existing market share for this molecule in the US, so the financial impact beyond the stated Rs 3.00 crores opportunity cannot be quantified precisely. No information has been provided on any concurrent corporate actions such as M&A, capex, fund-raising, or changes in leverage tied to this development. The news item also does not mention intraday stock price reaction or volumes on the exchanges, but such product-specific USFDA approvals are typically tracked by the market as potential earnings accretive events, even if on a relatively small base.
Kotak maintains Add rating on Concord Biotech with strong FY27–29 growth view
Stock NewsCONCORDBIO2 Jun 2026
Kotak Institutional Equities has maintained an Add rating on Concord Biotech with a revised target price of Rs 1,275. The brokerage notes that the company reported a sharp miss in Q4 earnings, which it attributes primarily to temporary external factors and an oversupply situation in the broader industry, rather than structural issues with the core business franchise. Despite the near-term disappointment, Kotak highlights that management has guided for more than 18 percent sales growth in FY27, supported by a healthy demand pipeline and improving operating environment as temporary headwinds subside.
Kotak’s research outlines strong revenue visibility for the first half of FY27, indicating that a meaningful portion of projected orders and contracts is already in place, which underpins confidence in the medium-term growth trajectory. The brokerage is building in about 24 percent and 21 percent sales growth for FY27 and FY28, respectively, reflecting expectations of normalization in utilisation and a better pricing environment once industry oversupply eases. Over FY26–29, Kotak estimates around 29 percent compound annual growth in earnings per share, driven by higher capacity utilisation, a slate of new product launches, and market share gains in key active pharmaceutical ingredient and related segments. The note implies that, while near-term performance was weaker than anticipated, the structural earnings and growth outlook remains robust, and the current valuation coupled with the medium-term projections justifies retaining a positive stance through an Add recommendation.
Jefferies keeps Hold rating on Concord Biotech after weak Q4 print
Stock NewsCONCORDBIO2 Jun 2026
Concord Biotech is in focus after global brokerage Jefferies maintained its Hold rating on the stock while setting a target price of Rs 1,020. The brokerage decision follows a weak Q4 performance, which it attributes to delayed customer orders, regulatory approvals and procurement-related issues impacting near-term revenue recognition. These operational bottlenecks appear to have weighed on recent quarterly numbers, limiting immediate earnings momentum despite an otherwise healthy underlying demand environment.
Management has provided an optimistic medium-term outlook, guiding for approximately 20 percent revenue growth by FY27 along with an expectation of improved EBITDA margins. This suggests a potential recovery and scaling up of profitability over the next few years, assuming timely execution and normalization of the current disruptions. The commentary indicates that operational efficiency gains and better capacity utilization could support margin expansion as revenue builds up.
However, Jefferies also highlights that customer tender delays remain an overhang and key risk factor. Persistent or incremental delays in large tender-driven businesses may continue to create volatility in quarterly revenues and limit visibility on short-term performance, even though order visibility for 1HFY27 is described as strong. Overall, the brokerage stance and target price reflect a balanced view between near-term execution risks arising from delays and the company’s guided growth trajectory and margin improvement potential into FY27.
Concord Biotech informs about press release
Stock NewsCONCORDBIO30 May 2026
NULL
Concord Biotech upbeat on FY27 growth outlook from products, customers mix shift
Stock NewsCONCORDBIO30 May 2026
Concord Biotech Limited has indicated that it remains optimistic about delivering strong growth in FY27, driven primarily by product expansion and customer diversification. The company appears focused on broadening its product portfolio, which is likely to include a wider range of niche and high-value formulations or active pharmaceutical ingredients, helping it address more therapeutic segments and geographies. By expanding its offerings, Concord Biotech aims to deepen penetration with existing clients while also opening up fresh revenue streams from new markets and product categories. This strategy can potentially improve the company’s pricing power, reduce dependence on a narrow product basket, and support more resilient topline growth over the medium term.
In parallel, Concord Biotech is emphasising customer diversification as a structural pillar of its growth strategy. Increasing the number of customers across regions and market segments can mitigate concentration risk that typically arises when revenue is skewed towards a few large buyers. A broader and more balanced customer base can provide better earnings visibility, reduce vulnerability to order volatility from any single client, and support steadier capacity utilisation levels. In combination with product expansion, this diversification focus is likely to enhance business stability and may help the company sustain growth even amid competitive pressures or regulatory changes in specific markets. While no specific financial metrics, capex plans, or margin guidance are disclosed in the available context, the articulated optimism around FY27 suggests management is confident that its current pipeline of products and relationships with a wider set of customers will provide a solid platform for future revenue and profit growth.

